- Home
- AMSF vs LENZ Comparison
AMSF vs LENZ Comparison
Compare AMSF & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- LENZ
- Stock Information
- Founded
- AMSF 1985
- LENZ 2019
- Country
- AMSF United States
- LENZ United States
- Employees
- AMSF N/A
- LENZ N/A
- Industry
- AMSF Accident &Health Insurance
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- AMSF Finance
- LENZ Health Care
- Exchange
- AMSF Nasdaq
- LENZ Nasdaq
- Market Cap
- AMSF 971.0M
- LENZ 614.9M
- IPO Year
- AMSF 2005
- LENZ 2021
- Fundamental
- Price
- AMSF $51.26
- LENZ $23.64
- Analyst Decision
- AMSF Buy
- LENZ Strong Buy
- Analyst Count
- AMSF 2
- LENZ 6
- Target Price
- AMSF $59.50
- LENZ $35.40
- AVG Volume (30 Days)
- AMSF 98.9K
- LENZ 184.4K
- Earning Date
- AMSF 02-19-2025
- LENZ 11-06-2024
- Dividend Yield
- AMSF 2.91%
- LENZ N/A
- EPS Growth
- AMSF N/A
- LENZ N/A
- EPS
- AMSF 3.21
- LENZ N/A
- Revenue
- AMSF $315,182,000.00
- LENZ N/A
- Revenue This Year
- AMSF N/A
- LENZ N/A
- Revenue Next Year
- AMSF $0.88
- LENZ N/A
- P/E Ratio
- AMSF $15.84
- LENZ N/A
- Revenue Growth
- AMSF 2.81
- LENZ N/A
- 52 Week Low
- AMSF $41.97
- LENZ $2.57
- 52 Week High
- AMSF $60.24
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- AMSF 47.57
- LENZ 29.32
- Support Level
- AMSF $48.38
- LENZ $21.80
- Resistance Level
- AMSF $50.20
- LENZ $33.79
- Average True Range (ATR)
- AMSF 0.81
- LENZ 1.60
- MACD
- AMSF 0.16
- LENZ -0.73
- Stochastic Oscillator
- AMSF 84.38
- LENZ 10.96
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance to employers engaged in hazardous industries, mainly construction, trucking, manufacturing, oil and gas, and agriculture. The company generates a majority of its revenue in the form of premiums.
About LENZ LENZ Therapeutics Inc. Common Stock
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.